CEVEC aims to become the leading independent player for human cell line based clinical materials. CEVEC offers the human amniocyte based protein expression platform CAP for the transient and stable production of biopharmaceuticals.
CEVEC aims to become the leading independent player for human cell line based clinical materials. CEVEC offers the human amniocyte based protein expression platform CAP for the transient and stable production of biopharmaceuticals.
Ayoxxa is a biotech company offering a revolutionary technology platform for protein multiplexing. Getting more relevant results within a short period of time makes Ayoxxa’s technology highly efficient.